pyrazines has been researched along with Aneuploid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC | 1 |
2 other study(ies) available for pyrazines and Aneuploid
Article | Year |
---|---|
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Male; Metaphase; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2010 |